As­traZeneca views $2B+ Fu­sion buy­out as ‘start­ing point’ for bet­ter ra­dio­phar­ma­ceu­ti­cals, com­bos

As the fifth ma­jor phar­ma play­er to stake a claim in ra­dio­phar­ma­ceu­ti­cals, As­traZeneca sees big po­ten­tial in im­prov­ing on cur­rent op­tions and ex­plor­ing com­bi­na­tion can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER